Johnson & Johnson knows the time has come for its blockbuster immunology drug Stelara (ustekinumab), which brought in $10.9bn in 2023.
“We know that Stelara is near or at its end of life,” said the firm’s executive vice president and worldwide...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?